Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 10, 2023

SELL
$125.51 - $229.3 $2.85 Million - $5.2 Million
-22,698 Reduced 51.16%
21,670 $4.77 Million
Q3 2022

Nov 03, 2022

BUY
$131.8 - $202.24 $691,818 - $1.06 Million
5,249 Added 13.42%
44,368 $5.98 Million
Q2 2022

Aug 09, 2022

SELL
$121.11 - $216.05 $244,157 - $435,556
-2,016 Reduced 4.9%
39,119 $6.33 Million
Q1 2022

May 09, 2022

BUY
$146.52 - $269.56 $1.44 Million - $2.65 Million
9,834 Added 31.42%
41,135 $7.76 Million
Q4 2021

Feb 10, 2022

SELL
$248.56 - $389.34 $2.86 Million - $4.49 Million
-11,523 Reduced 26.91%
31,301 $8.48 Million
Q3 2021

Nov 09, 2021

BUY
$249.6 - $403.14 $2.88 Million - $4.65 Million
11,543 Added 36.9%
42,824 $15.5 Million
Q2 2021

Aug 05, 2021

BUY
$292.75 - $367.01 $401,067 - $502,803
1,370 Added 4.58%
31,281 $10.7 Million
Q1 2021

May 11, 2021

BUY
$260.64 - $382.12 $6.23 Million - $9.13 Million
23,902 Added 397.77%
29,911 $10.4 Million
Q4 2020

Feb 11, 2021

SELL
$221.31 - $316.61 $4.35 Million - $6.22 Million
-19,634 Reduced 76.57%
6,009 $1.55 Million
Q3 2020

Nov 02, 2020

BUY
$189.18 - $286.44 $4.35 Million - $6.59 Million
23,000 Added 870.22%
25,643 $7.35 Million
Q2 2020

Aug 11, 2020

BUY
$123.9 - $195.41 $1,362 - $2,149
11 Added 0.42%
2,643 $498,000
Q1 2020

May 05, 2020

BUY
$121.84 - $173.19 $1,705 - $2,424
14 Added 0.53%
2,632 $324,000
Q4 2019

Feb 06, 2020

SELL
$115.78 - $208.34 $1.36 Million - $2.44 Million
-11,729 Reduced 81.75%
2,618 $434,000
Q3 2019

Oct 28, 2019

SELL
$120.61 - $148.29 $99,262 - $122,042
-823 Reduced 5.43%
14,347 $1.76 Million
Q2 2019

Aug 05, 2019

BUY
$113.99 - $146.86 $564,934 - $727,838
4,956 Added 48.52%
15,170 $1.88 Million
Q1 2019

May 06, 2019

BUY
$122.82 - $151.83 $740,481 - $915,383
6,029 Added 144.06%
10,214 $1.35 Million
Q4 2018

Mar 04, 2019

BUY
$107.01 - $175.15 $447,836 - $733,002
4,185 New
4,185 $587,000

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $20.8B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Teacher Retirement System Of Texas Portfolio

Follow Teacher Retirement System Of Texas and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Teacher Retirement System Of Texas, based on Form 13F filings with the SEC.

News

Stay updated on Teacher Retirement System Of Texas with notifications on news.